Genetic testing of ocular manifestations of proliferative syndrome to provide pathophysiology-oriented treatment
DOI: 10.32364/2311-7729-2022-22-1-16-22
M.E. Weener1, N.A. Bakunina2,3, J.M. Salmasi4, G.V. Poryadin4, D. Barh1, Yu.D. Kuznetsova2, L.M. Balashova2,4
1LLC "Oftalmic", Moscow, Russian Federation
2Non-profit partnership "International Scientific and Practical Center for the Proliferation of Tis-sues of Russia", Moscow, Russian Federation
3N.I. Pirogov City Clinical Hospital No. 1, Moscow, Russian Federation
4Pirogov Russian National Research Medical University, Moscow, Russian Federation
Background: uncontrolled cell proliferation of the ocular blood network is one of the leading causes of blindness and low vision worldwide. We summarize relevant published data and our 5-year experience in searching treatment tools for excessive non-productive proliferation.
Aim: to describe genetic patterns in patients with ocular blood network proliferation for predicting disease course and selecting adequate treatment.
Patients and Methods: 1210 patients with proliferative ocular disorders, retinopathy of prematurity, and diabetes were enrolled. Patients were divided into three groups: (1) monogenic disorders, (2) proliferative vitreoretinopathy and diabetes mellitus, (3) retinopathy of prematurity. Follow-up was 6 to 36 months. Laboratory, genetic, and relevant clinical tests were pursued in all patients.
Results: proprietary approach of bioinformatic analysis of whole exome/whole genome sequencing data allows for specifying the proliferative process’s prognosis and severity given clinical and genetic findings. This approach includes the analysis of gene mutations directly or indirectly involved in angiogenesis and key signaling pathways. The analysis of mutation identified in group 2 revealed 509C>T TGFB1 gene polymorphism in two patients and c.3174G>A IGF1R gene polymorphism in three patients. In group 3, the most common VEGFA gene polymorphisms were +13553C>T, -634G>C, +405G>C (rs2010963), and -460C>T (rs833061).
Conclusion: specifying the prognosis of the course and severity of proliferative ocular disorders pathogenically-oriented targeted treatment requires specialized genetic testing using an improved data analysis approach.
Keywords: proliferative syndrome, diabetes, retinopathy of prematurity, VEGFA, TGFB1, IGF1R, Stickler syndrome, Wagner syndrome, Wolframe syndrome, Marshall syndrome, Norrie disease, Coats disease, retinoschisis.
For citation: Weener M.E., Bakunina N.A., Salmasi J.M. et al. Genetic testing of ocular manifestations of proliferative syndrome to provide pathophysiology-oriented treatment. Russian Journal of Clinical Ophthalmology. 2022;22(1):16–22 (in Russ.). DOI: 10.32364/2311-7729-2022-22-1-16-22.
About the authors:
1Marianna E. Weener — C. Sc. (Med.), Head; ORCID iD 0000-0002-1089-4293.
2,3Natalia A. Bakunina — C. Sc. (Med.), ophthalmologist; ORCID iD 0000-0002-1148-5184.
4Jean M. Salmasi — Dr. Sc. (Med.), Professor, Head of the Department of Pathophysiology; ORCID iD 0000-0001-8524-0019.
4Gennadiy V. Poryadin — Dr. Sc. (Med.), Professor, Corresponding Member of the RAS, Honorary Head of the Department of Pathophysiology; ORCID iD 0000-0003-2010-3296.
1Debmalya Barh — PhD, bioinformatician; ORCID iD 0000-0002-2557-7768.
2Yulia D. Kuznetsova — ophthalmologist, ORCID iD 0000-0002-4715-5873.
2,4 Larisa M. Balashova — Dr. Sc. (Med.), Professor, Head; ORCID iD 0000-0001-9349-7092.
1LLC "Oftalmic", 47/3, Leningradskiy av., Moscow, 125167, Russian Federation.
2Non-profit partnership "International Scientific and Practical Center for the Proliferation of Tissues of Russia", 29/14, Prechistenka str., Moscow, 119034, Russian Federation.
3N.I. Pirogov City Clinical Hospital No. 1, 8, Leninskiy av., Moscow, 119049, Russian Federation.
4Pirogov Russian National Research Medical University, 1, Ostrovityanov str., Moscow, 117997, Russian Federation.
Contact information: Marianna E. Weener, e-mail: info@oftalmic.ru.
Financial Disclosure: Marianna E. Weener and Debmalya Barh are employees of the LLC "Oftalmic". Larisa M. Balashova, Natalia A. Bakunina, and Yulia D. Kuznetsova are employees of the International Scientific and Practical Center for Tissue Proliferation. Other authors declare no conflict of interests.
Received 13.07.2020.
2. Chen J.F., Zhang S., Zhou R. et al. Adenosine receptors and caffeine in retinopathy of prematurity. Mol Aspects Med. 2017;(55):118–125. DOI: 10.1016/j.mam.2017.01.001.
3. Swan R., Kim S.J., Campbell J.P. et al. The genetics of retinopathy of prematurity: a model for neovascular retinal disease. Ophthalmol Retina. 2018;2(9):949–962. DOI: 10.1016/j.oret.2018.01.016.
4. Selvam S., Kumar T., Fruttiger M. Retinal vasculature development in health and disease. Prog Retin Eye Res. 2018;63:1–19. DOI: 10.1016/j.preteyeres.2017.11.001.
5. Kim S.J., Port A.D., Swan R. et al. Retinopathy of Prematurity: A Review of Risk Factors and their Clinical Significance. Surv Ophthalmol. 2018;63(5):618–637. DOI: 10.1016/j.survophthal.2018.04.002.
6. Nashwa S.Z., Khair M., Ismail A.S. et al. Detection of FZD4, LRP5 and TSPAN12 genes variants in Malay premature babies with retinopathy of prematurity. J Ophthalmic Vis Res. 2019;14(2):171–178. DOI: 10.4103/jovr.jovr_210_17.
7. Malaichamy S., Yohe S., Ghosh A. et al. Prevalence of mutations in inherited retinal diseases: A comparison between the United States and India. Mol Genet Genomic Med. 2020;8:e1081. DOI: 10.1002/mgg3.1081.
8. Roudnicky F., Zhang J.D., Kim B.K. et al. Inducers of the endothelial cell barrier identified through chemogenomic screening in genome-edited hPSC-endothelial cells. Proc Natl Acad Sci USA. 2020;117(33):19854–19865. DOI: 10.1073/pnas.1911532117.
9. Wang Y., Wang X., Wang Y.X. et al. The Long-Noncoding RNA TUG1 Regulates Oxygen-Induced Retinal Neovascularization in Mice via MiR-299. Invest Ophthalmol. Vis Sci. 2022;63(1):37. DOI: 10.1167/iovs.63.1.37.
10. Wojnarowicz P.M., Silva R.L., Ohnaka M. A small-molecule pan-Id antagonist inhibits. pathologic ocular neovascularization. Cell Rep. 2019;29(1):62–75. DOI: 10.1016/j.celrep.2019.08.073.
11. Graham P.S., Kaidonis G., Abhary S. et al. Genome-wide association studies for diabetic macular edema and proliferative diabetic retinopathy. BMC Med Genet. 20188;19(1):71. DOI: 10.1186/s12881-018-0587-8.
12. Pollack S., Igo R.P. Jr, Jensen R.A. et al. Multiethnic Genome-Wide Association Study of Diabetic Retinopathy Using Liability Threshold Modeling of Duration of Diabetes and Glycemic Control. Diabetes. 2019;68(2):441–456. DOI: 10.2337/db18-0567.
13. Grassi M.A., Tikhomirov A., Ramalingam S. et al. Genome-wide meta-analysis for severe diabetic retinopathy. Hum Mol Genet. 2011;20(12):2472–2481. DOI: 10.1093/hmg/ddr121.
14. Pietrzyk J.J., Kwinta P., Bik-Multanowski M. et al. New insight into the pathogenesis of retinopathy of prematurity: assessment of whole-genome expression. Pediatr Res. 2013;73(4 Pt 1):476–483. DOI: 10.1038/pr.2012.195.
15. Tao T., Meng X., Xu N. et al. Ocular phenotype and genetical analysis in patients with retinopathy of prematurity. BMC Ophthalmol. 2022;22(1):22. DOI: 10.1186/s12886-022-02252-x.
16. Guo Y., Du F., Tan Y.L. et al. VEGF-mediated angiogenesis in retinopathy of prematurity is co-regulated by miR-17–5p and miR-20a-5p. Biochem Cell Biol. 2021;99(4):414–423. DOI: 10.1139/bcb-2020-0357.
17. Балашова Л.М., Борзун Н.С., Ажугим М.Н. Задняя гиалоидная мембрана: анатомо-физиологические особенности, роль в развитии витреоретинальной пролиферации. Клиническая офтальмология. 2002;2:78. [Balashova L.M., Borzun N.S., Azhugim M.N. Posterior hyaloid membrane: anatomical and. physiological features, role in the development of vitreoretinal proliferation. Clinical.Ophthalmology. 2002;2:78 (in Russ.)].
18. Балашова Л.М., Попов А.В. Патент на изобретение № 2440159 от 20.01.2012. «Способ торможения процессов пролиферации в сетчатке при ее повреждении». [Balashova L.M., Popov A.V. Patent for invention No. 2440159 dated January. 20, 2012 "Method of inhibition of proliferation processes in the retina when it is. damaged" (in Russ.)].
This work is licensed under a Creative Commons «Attribution» 4.0 License.
